SCHEMBL4524528

SCHEMBL4524528

C=CCc1nc2sc(C(=O)OCC)c(C)c2c(=O)[nH]1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.61
MEN1 O00255 6/20 0.61
L3MBTL1 Q9Y468 3/20 0.59
PIP4K2A P48426 1/20 0.59
ALDH1A1 P00352 6/20 0.57
MAPT P10636 6/20 0.54
KDM4E B2RXH2 5/20 0.54
GAA P10253 2/20 0.54
RXFP1 Q9HBX9 2/20 0.54
LMNA P02545 2/20 0.54
PPARG P37231 1/20 0.54
NCOA2 Q15596 1/20 0.54
HPGD P15428 2/20 0.53
CYP1A2 P05177 1/20 0.53
POLB P06746 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
PKM P14618 1/20 0.52
MAPK1 P28482 2/20 0.50
HSD17B10 Q99714 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3493231 0.85 ALDH1A1 (0.58) KMT2AMEN1L3MBTL1ALDH1A1MAPT
SCHEMBL4523689 0.84 KMT2A (0.66) KMT2AMEN1L3MBTL1PIP4K2AALDH1A1
SCHEMBL4523978 0.82 KMT2A (0.62) KMT2AMEN1L3MBTL1PIP4K2AALDH1A1
SCHEMBL4505517 0.82 KMT2A (0.62) KMT2AMEN1L3MBTL1PIP4K2AALDH1A1
SCHEMBL4514858 0.81 KMT2A (0.67) KMT2AMEN1L3MBTL1PIP4K2AALDH1A1
SCHEMBL4927869 0.81 KDM4E (0.78) KMT2AMEN1L3MBTL1PIP4K2AALDH1A1
SCHEMBL4524089 0.81 MAPT (0.74) KMT2AMEN1L3MBTL1PIP4K2AALDH1A1
SCHEMBL4519850 0.81 KMT2A (0.66) KMT2AMEN1L3MBTL1PIP4K2AALDH1A1
SCHEMBL4505918 0.80 KMT2A (0.60) KMT2AMEN1L3MBTL1PIP4K2AALDH1A1
SCHEMBL4525316 0.80 KMT2A (0.66) KMT2AMEN1L3MBTL1PIP4K2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 KMT2A 2650/4885MEN1 2509/4885L3MBTL1 602/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 KMT2A 2650/4885MEN1 2509/4885L3MBTL1 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.